Anti-IgE Treatment for Disorders Other Than Asthma
- PMID: 28983485
- PMCID: PMC5613080
- DOI: 10.3389/fmed.2017.00152
Anti-IgE Treatment for Disorders Other Than Asthma
Abstract
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.
Keywords: allergy; asthma; immunotherapy; omalizumab; urticaria.
Similar articles
-
The use of anti-IgE therapy beyond allergic asthma.J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):162-6. doi: 10.1016/j.jaip.2014.10.010. Epub 2015 Jan 16. J Allergy Clin Immunol Pract. 2015. PMID: 25609342 Review.
-
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. doi: 10.2174/1568010043343615. Curr Drug Targets Inflamm Allergy. 2004. PMID: 15379589 Review.
-
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. doi: 10.2174/187221307782418900. Recent Pat Inflamm Allergy Drug Discov. 2007. PMID: 19075985 Review.
-
Omalizumab : other indications and unanswered questions.Clin Rev Allergy Immunol. 2005 Aug;29(1):17-30. doi: 10.1385/CRIAI:29:1:017. Clin Rev Allergy Immunol. 2005. PMID: 16222081 Review.
-
Current and future applications of the anti-IgE antibody omalizumab.Biologics. 2008 Mar;2(1):67-73. doi: 10.2147/btt.s1800. Biologics. 2008. PMID: 19707429 Free PMC article.
Cited by
-
Efficacy of long-term treatment with omalizumab in a food and inhalant allergy patient.Postepy Dermatol Alergol. 2020 Jun;37(3):441-442. doi: 10.5114/ada.2020.96111. Epub 2020 Jul 16. Postepy Dermatol Alergol. 2020. PMID: 32792891 Free PMC article. No abstract available.
-
Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Naunyn Schmiedebergs Arch Pharmacol. 2020 Sep;393(9):1573-1580. doi: 10.1007/s00210-020-01886-2. Epub 2020 May 6. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 32377770 Free PMC article. Review.
-
Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey.Postepy Dermatol Alergol. 2019 Dec;36(6):734-738. doi: 10.5114/ada.2019.91424. Epub 2019 Dec 30. Postepy Dermatol Alergol. 2019. PMID: 31998003 Free PMC article.
-
Attenuated asthma phenotype in mice with a fetal-like antigen receptor repertoire.Sci Rep. 2021 Jul 9;11(1):14199. doi: 10.1038/s41598-021-93553-6. Sci Rep. 2021. PMID: 34244568 Free PMC article.
-
Omalizumab for successful chemotherapy desensitisation: What we know so far.Clin Transl Allergy. 2021 Dec 13;11(10):e12086. doi: 10.1002/clt2.12086. eCollection 2021 Dec. Clin Transl Allergy. 2021. PMID: 34938440 Free PMC article. Review.
References
-
- Vercelli D. Immunobiology of IgE. 7th ed In: Adkinson N, Bochner BS, Busse WW, et al., editors. Middleton’s Allergy: Principles and Practice. Mosby Elsevier; (2009).
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources